

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 403/14, 403/02, 401/14, 401/02, A61K 31/495, 31/435, 31/155</b>		A1	(11) International Publication Number: <b>WO 98/46597</b>
			(43) International Publication Date: 22 October 1998 (22.10.98)
(21) International Application Number: PCT/US98/07709		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 14 April 1998 (14.04.98)			
(30) Priority Data: 60/043,640 14 April 1997 (14.04.97) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): EMORY UNIVERSITY [US/US]; 1380 S. Oxford Road, Atlanta, GA 30322 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): LIOTTA, Dennis, C. [US/US]; 251 Montrose Drive, McDonough, GA 30253 (US). NEVINS, Neysa [US/US]; 5343 O'Reilly Lane, Stone Mountain, GA 30088 (US). SNYDER, James, P. [US/US]; 1086 Rosedale Drive, N.E., Atlanta, GA 30306 (US). ZHANG, Dawei [CN/US]; 1501 Clairmont Road #736, Decatur, GA 30033 (US). KASDORF, Krista [US/US]; 419 N.E. 2nd Avenue, Fort Lauderdale, FL 33301 (US).			
(74) Agents: PRATT, John, S. et al.; Kilpatrick Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309-4530 (US).			

(54) Title: SERINE PROTEASE INHIBITORS

## (57) Abstract

Compounds such as (A) or its pharmaceutically acceptable salts or hydrates, inhibit viral and human serine proteases, and are suitable for the treatment of hepatitis C virus infection, human cytomegalovirus infection, yellow fever, viral encephalitis, pulmonary emphysema, cardiovascular disease, cancer, rheumatoid arthritis, herpes, and immune nephritis.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF THE INVENTION  
SERINE PROTEASE INHIBITORS

BACKGROUND OF THE INVENTION

5 Proteases are essential enzymes in the life cycle of many viruses and also play a role in various physiological processes. Many of the proteases developed by viruses are so specialized that they differ substantially from the enzymes to be found in the host, and such specialization makes the viral protease an attractive target of drug therapy. Proteases are also used by the body to regulate various processes and an  
10 imbalancing of these mechanisms leads to many disease states. Inhibition of protease, such as serine protease, is considered an ideal chemotherapy in such cases.

Viruses suitable for serine protease inactivation include hepatitis C virus (HCV), [Love, R. A., et al.; *Cell* 87, 331 (1996); Kim, J. L., et al., *Cell* 87, 343 (1996)], human cytomegalavirus (HCMV) [Stevens, J. T., et al., *Eur. J. BioChem.* 226, 361  
15 (1994)], various flaviviruses, e.g., yellow fever, various encephalitises [Fraenkel-Conrat, H., et al., *Virology*, 2nd Ed., Prentice Hall Englewood Cliffs, pp. 102-103 (1998)], as well as HSV-1, HSV-2, VZV, EBV, HHV-6, and HHV-7.

In the host, human leukocyte elastase (HLE) is a serine protease which is involved in diseases such as pulmonary emphysema, [Lungarella, G., et al., *Exp. Mol.*  
20 *Pathol.* 42, 44 (1985); Powers, J. C. *Trends BioChem. Sci.*, 1 (9), 211 (1976)], arthritis [Janoff, A. et al. (eds.) *Neutral Proteases in Human Polymorphonuclear Leukocytes*, Urban and Schwartzberg, Baltimore, p. 390-417, (1978); Janoff, A. *Molecular Basis of Biological Degradative Processes*, Berlin, R.D., et al., (Eds.), Academic Press, New York, pp. 225-260, (1973)], pancreatitis [Geokas, M.C., et al., *Lab. Invest.* 19, 235  
25 (1968)], adult respiratory distress syndrome [Burchardi, H., et al., *Adv. Exp. Med. Biol.* 167, 319 (1984)] and various degenerative skin disorders. The serine proteases involved with these diseases are of great interest as drug targets. Other physiological serine proteases include thrombin, which is implicated in many cardiovascular diseases [Fox, I., et al., *Thromb. Haemostasis* 69, 157(1993); Maffrand, J.P. *Nouv. Rev. Fr. Hemato.*  
30 34, 405 (1992)]; urokinase-type plasminogen activator (UPA), which is known to aid in the metastasis of some types of cancer [Mueller, B. M., *Curr. Top. Microbiol. Immuno.* 213, 65 (1996); Schmitt, M., et al., *J. Obstet. Gynaecol.* 21, 151 (1995)], especially

prostate [Rabbani, S. A., et al., *Int. J. Cancer* 63, 840, (1995); Soff, G. A., et al., *J. Clin. Invest.* 96, 2593 (1995)], gastric [Herszenyi, L., et al., *Acta Physiol. Hung.* 83, 213 (1995); Plebani, M., et al., *Cancer* 76, 367 (1995)], and breast [Duffy, M. J., et al., *Enzyme Protein* 49, 85, (1996); Xing, R. H., et al., *Int. J. Cancer* 67, 423, (1996)]; and  
5 collagenase, which plays a role in destructive corneal disease associated with rheumatoid arthritis (Riley, G. P., et al., *Eye* 9(6), 703 (1995)]. Serine proteases are also implicated in immune nephritis [Hruby, Z., et al., *Int. Urol. Nephrol.* 20, 513 (1988); Hruby, Z., et al., *Nephrol. Dial. Transplant* 11, 32, (1996)].

Applicants have discovered new compounds useful for inhibition of  
10 serine protease as a drug target.

#### BRIEF DESCRIPTION OF THE INVENTION

Compounds of formulas I-III, as herein defined, are disclosed. These compounds are useful in the inhibition of the serine protease encoded by HCV, HCMV,  
15 flaviviruses involved with yellow fever or encephalitis, Herpes Simplex Virus, VZV, Epstein Barr Virus, and HHV. These compounds are also suitable for the treatment of infection by such viruses, the prevention of infection by such viruses, and in the treatment of diseases resulting from infection of such viruses. The compounds of the present invention are also useful for treating diseases without apparent viral etiology,  
20 including pulmonary emphysema, cardiovascular disease, cancer, rheumatoid arthritis and immune nephritis.

For such purposes, compounds of formulas I-III are suitable, either as compounds, pharmaceutically acceptable salts or hydrates, pharmaceutical composition ingredients, whether or not as combination with other antivirals, immunomodulators,  
25 antibiotics or vaccines. Methods of treating infection by such viruses, and methods of preventing infection by such viruses are also disclosed.

Some abbreviations that may appear in this application follow:


ABBREVIATIONS

	EBV	Epstein Barr Virus
5	HCV	Hepatitis C Virus
	HCMV	Human Cytomegalovirus
	HHV	Human Herpes Virus
	HLE	Human Leukocyte Elastase
	HSV	Herpes Simplex Virus, in various
10		serotypes, e.g., HSV-1, HSV-2
	MCPBA	3-Chloroperoxybenzoic acid
	UPA	Urokinase-type Plasminogen
	VZV	Varicella Zoster Virus

15                   DETAILED DESCRIPTION OF THE INVENTION

This invention relates to compounds of formula I-III, combinations thereof, or pharmaceutically acceptable salts or hydrates thereof, in the inhibition of serine protease encoded by HCV, HCMV, HSV, VZV, EBV, HHV, and flaviviruses involved with yellow fever or encephalitis. The compounds of the present invention are  
20 also useful for treating diseases without apparent viral etiology, including pulmonary emphysema, cardiovascular disease, cancer, rheumatoid arthritis and immune nephritis.

Compounds of formula I are defined as follows:



wherein:

—X is a single or a double bond;

X is C or N;

10  $R^1$  and  $R^4$  are independently selected from the groups consisting of

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl;
- (iii) aryl;
- (iv)  $C_{1-6}$ -OR, wherein R is H,  $C_{1-6}$  alkyl or aryl;
- 15 (v)  $C_{1-6}$ -SR; and
- (vi)  $C_{1-6}$ -NR<sub>2</sub>;

$R^2$  is

- (i) OH;
- (ii)  $C_{1-6}$  alkyl;
- 20 (iii) O- $C_{1-6}$  alkyl;
- (vi) aryl;
- (v)  $C_{1-6}$ OR;
- (vi)  $C_{1-6}$ -SR; or
- (vii)  $C_{1-6}$ -NR<sub>2</sub>;

$R^5$  is

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl;
- (iii) aryl;

5 when X is C or when X is N and

-----X is a single bond,

$R^3$  is H or  $(CH_2)_n-Q$ , wherein n is an integer between 1 and 5 and Q is

- (i) OH;
- 10 (ii)  $NH_2$ ;
- (iii) NHR;
- (iv)  $NR_2$ ;
- (v)  $COOH$ ;
- (vi)  $COOR$ ;
- 15 (vii) SH;
- (vii)  $S(O)R$ ; or
- (vii) SR;

when X is N and

-----X is a double bond,

20  $R^3$  is absent;

when either  $Y_1$  or  $W_1$  are hydrogen or  $Y_1$  and  $W_1$  are both hydrogens, then  $Z_1$  is absent,  $Y_1$  and  $W_1$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- 25 (ii)  $C_{1-6}$  alkyl; or
- (iii) aryl;

when  $Y_1$  and  $W_1$  are both not hydrogen, they are selected independently from:

- (i)  $-CH_2-$ ;
- (ii)  $-CHR^1-$ ; or
- 30 (iii)  $-CR^1R^4-$ ;

when either  $Y_2$  or  $W_2$  are hydrogen or  $Y_2$  and  $W_2$  are both hydrogens, then  $Z_2$  is absent,  $Y_2$  and  $W_2$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl; or
- (iii) aryl;

when  $Y_2$  and  $W_2$  are both not hydrogen, they are selected independently from:

- (i)  $-CH_2-$ ;
- (ii)  $-CHR^1-$ ; or
- (iii)  $-CR^1R^4-$ ;

$W_3$  is selected from:

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl; or
- (iii) aryl;

$U$  is selected independently from:

- (i) hydrogen;
- (ii)  $-C(O)-C_{1-6}$  alkyl;
- (iii)  $-C(O)-aryl$ ;
- (iv)  $-C(O)-O-C_{1-6}$  alkyl;
- (v)  $-C(O)-O-aryl$ ;
- (vi)  $-C(O)-NH-C_{1-6}$  alkyl; or
- (vii)  $-C(O)-NH-aryl$ ;


$Z_1$  and  $Z_2$  are selected independently from:

- (i)  $-CH_2-$ ;
- (ii)  $-CHR^1-$ ;
- (iii)  $-CR^1R^4-$ ; or
- (iv)  $-CH_2CH_2-$ ;

or pharmaceutically acceptable salts or hydrates thereof.



Compounds of the formula II are defined as follows:



5 wherein:

$R^1$  and  $R^4$  are independently selected from the groups consisting of

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl;
- (iii) aryl;
- 10 (iv)  $C_{1-6}$ -OR, wherein R is H,  $C_{1-6}$  alkyl or aryl;
- (v)  $C_{1-6}$ -SR; and
- (vi)  $C_{1-6}$ -NR<sub>2</sub>;

$R^2$  is

- (i) OH;
- 15 (ii)  $C_{1-6}$  alkyl;
- (iii) O- $C_{1-6}$  alkyl;
- (iv) aryl;
- (v)  $C_{1-6}$ -OR;
- (vi)  $C_{1-6}$ -SR; or
- 20 (vii)  $C_{1-6}$ -NR<sub>2</sub>;

$R^3$  is H or  $(CH_2)_n$ -Q, wherein n is an integer between 1 and 5 and Q is

- (i) OH;
- (ii) NH<sub>2</sub>;
- (iii) NHR;

- (iv)  $\text{NR}_2$ ;
- (v)  $\text{COOH}$ ;
- (vi)  $\text{COOR}$ ;
- (vii)  $\text{SH}$ ;
- (viii)  $\text{S(O)R}$ ; or
- (ix)  $\text{SR}$ ;

$\text{R}^5$  is

- (i) hydrogen;
- (ii)  $\text{C}_{1-6}$  alkyl; or
- (iii) aryl;

when either  $\text{Y}_1$  or  $\text{W}_1$  are hydrogen or  $\text{Y}_1$  and  $\text{W}_1$  are both hydrogens, then  $\text{Z}_1$  is absent,  $\text{Y}_1$  and  $\text{W}_1$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- (ii)  $\text{C}_{1-6}$  alkyl; or
- (iii) aryl;

when  $\text{Y}_1$  and  $\text{W}_1$  are both not hydrogen, they are both  $-\text{CH}_2-$ ;

when either  $\text{Y}_2$  or  $\text{W}_2$  are hydrogen or  $\text{Y}_2$  and  $\text{W}_2$  are both hydrogens, then  $\text{Z}_2$  is absent,  $\text{Y}_2$  and  $\text{W}_2$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- (ii)  $\text{C}_{1-6}$  alkyl; or
- (iii) aryl;

when  $\text{Y}_2$  and  $\text{W}_2$  are both not hydrogen, they are both  $-\text{CH}_2-$ ;

$\text{W}_3$  is:

- (i) hydrogen
- (ii)  $\text{C}_{1-6}$  alkyl; or
- (iii) aryl;

$\text{U}$  is:


- (i) hydrogen;
- (ii)  $-\text{C(O)}-\text{C}_{1-6}$  alkyl;

- (iii) -C(O)-aryl;
- (iv) -C(O)-O-C<sub>1-6</sub> alkyl;
- (v) -C(O)-O-aryl;
- (vi) -C(O)-NH-C<sub>1-6</sub> alkyl;
- (vi) -C(O)-NH-aryl;

Z<sub>1</sub> and Z<sub>2</sub> are both -CH<sub>2</sub>-;

or pharmaceutically acceptable salts or hydrates thereof.

Compounds of the formula III are defined as follows:



wherein:

R<sup>1</sup> is independently selected from the groups consisting of

- (i) hydrogen
- (ii) C<sub>1-6</sub> alkyl;
- (iii) aryl;
- (iv) C<sub>1-6</sub>-OR, wherein R is H, C<sub>1-6</sub> alkyl or aryl;
- (v) C<sub>1-6</sub>-SR; and
- (vi) C<sub>1-6</sub>-NR<sub>2</sub>;

R<sup>2</sup> is

- (i) hydrogen;
- (ii) C<sub>1-6</sub> alkyl; or
- (iii) aryl;

when either  $Y_1$  or  $W_1$  are hydrogen or  $Y_1$  and  $W_1$  are both hydrogens, then  $Z_1$  is absent,  $Y_1$  and  $W_1$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl; or
- (iii) aryl;

when  $Y_1$  and  $W_1$  are both not hydrogen, they are both  $-CH_2-$ ;

$W_2$  is:

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl; or
- (iii) aryl;

$U$  is:


- (i) hydrogen;
- (ii)  $-C(O)-C_{1-6}$  alkyl;
- (iii)  $-C(O)-$ aryl;
- (iv)  $-C(O)-O-C_{1-6}$  alkyl;
- (v)  $-C(O)-O-$ aryl;
- (vi)  $-C(O)-NH-C_{1-6}$  alkyl; or
- (vii)  $-C(O)-NH-$ aryl;

$Z_1$  is  $-CH_2-$ ;

or pharmaceutically acceptable salts or hydrates thereof.

Compound A is preferred and is defined as follows:

5



IV

or pharmaceutically acceptable salts or hydrates thereof.


The present invention also relates to a pharmaceutical composition comprising any compound of the present invention, and a pharmaceutically acceptable carrier.

The pharmaceutical composition of the present invention is useful in the treatment of infections associated with hepatitis C and human cytomeglavirus, encephalitis, pulmonary emphysema, cardiovascular disease, cancer, rheumatoid arthritis and immune nephritis.

The pharmaceutical composition of the present invention is useful in the inhibition of the serine proteases of HCV, HCMV, HSV, VZV, EBV and HHV.

The preferred compound of the present invention is compound A, shown below

**Compound A:**



6-Hydroxy-2-isopropyl-1,6-dihydro-2H-pyridin-3-one, or  
pharmaceutically acceptable salt or hydrate thereof.

The compounds of the present invention, may have asymmetric centers  
and occur as racemates, racemic mixtures and as individual diastereomers or  
5 enantiomers, with all isomeric forms being included in the present invention.

When any variable (e.g.,  $R^1$ ,  $R^2$ ) occurs more than one time in any  
constituent or in formulas I-III, its definition on each occurrence is independent of its  
definition at every other occurrence. Also, combinations of substituents and/or variables  
are permissible only if such combinations result in stable compounds.


10 As used herein except where noted, "alkyl" is intended to include both  
branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified  
number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl). As used  
herein, with exceptions as noted, "aryl" is intended to mean phenyl (Ph) or naphthyl.

The pharmaceutically-acceptable salts of the compounds of Formulas I-  
15 III (in the form of water- or oil-soluble or dispersible products) include the conventional  
non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic  
or organic acids or bases. Examples of such acid addition salts include acetate, adipate,  
alginate, aspartate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate,  
camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate,  
20 ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate,  
hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate,  
lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate,  
pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate,  
tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts,  
25 alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as  
calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts,  
N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.  
Also, the basic nitrogen-containing groups may be quaternized with such agents as  
lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and  
30 iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain  
halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl  
halides like benzyl and phenethyl bromides and others.

Schemes I-V for preparing the novel compounds of this invention are presented below. Schemes I-V are not limited by any particular substituents employed in the schemes for illustrative purposes. The examples specifically illustrate the application of the following schemes to specific compounds.

5 To synthesize the end group 13 of the present invention, the corresponding alpha-furfuryl amide 11 is synthesized as an intermediate. In Scheme I, the asymmetric synthesis of the alpha furfuryl amide is carried out by first subjecting 2-furaldehyde 1 to enantioselective alkylation with a chiral sulfonamide-titanate complex, formed with 2, to give 3 ( in the S configuration) with typically high enantiomeric excess. See, e.g.,  
10 Takahashi, H. et al., *Tetrahedron Lett.* 30, 7095 (1989), and Yoshioka, M. et al., *Tetrahedron Lett.* 30, 1657 (1989). Asymmetric conversion to the azide, followed by reduction to give amine 9 is accomplished by the method of Thompson, A. et al., *J.Org.Chem.* 58, 5886 (1993). Alternatively, acylated furan 5 is reacted with hydroxylamine to form the corresponding oxime, which in turn is reduced with lithium  
15 aluminum hydride (LAH) to give amine 6, typically in the S configuration, in the presence of either Noyori's reagent or Mosher's reagent. See, e.g., Smith, H.E., et al., *J.Am.Chem.Soc.* 101, 5186 (1979); Hutchins, R.O. et al., *J.Org.Chem.* 52, 704 (1987). Variations in Scheme I can provide either enantiomer. For example, inverting the configuration of both asymmetric carbons in 2 will give 3 in the R configuration.

## SCHEME I: Asymmetric Synthesis




- Scheme II sets forth three racemic pathways for the synthesis of intermediate racemate 9. In one pathway, furan 7 is acylated with catalyst  $\text{ZnCl}_2$  according to Harough, H.D. et al., *J. Am. Chem. Soc.* 69, 1012 (1947). The acylated furan 8 is then reacted with hydroxylamine to form the corresponding oxime, which in turn is reduced with lithium aluminum hydride (LAH) to give the racemic amine 9. See, e.g., Smith, H.E., et al., *J. Am. Chem. Soc.* 101, 5186 (1979). In a second pathway to synthesize racemic amine 9, 2-furaldehyde 1 is first reacted with the appropriate Grignard reagent to give the racemic alcohol 10. Conversion to the azide, followed by reduction to give racemic amine 9 is accomplished by the method of Thompson, A. et



al., *J.Org.Chem.* 58, 5886 (1993). A third method of synthesizing racemic amine **9** involves reacting the nonenolizable aldehyde **1** with 1,1,1,3,3,3-hexamethyldisilazane (LiHMDS) to give the corresponding N-trimethylsilyl imine, which is then treated with the appropriate Grignard reagent to give **9**. Tosylation of amine **9** gives **11** in Scheme

5 III.


## SCHEME II: Racemic Pathways



Oxidative rearrangements of 11 are carried out to isolate 13. See, for example, Scheme III. In the methods of Zhou, W.-S. et al., *Tetrahedron* **49**, 2641 (1993), Sharpless asymmetric epoxidation of racemic 11 using tert-butyl hydroperoxide (TBHP) in the presence of chiral titanium-tartrate catalyst gives a mixture of 12 and 13.


Alternatively, L-(+)-DIPT gives a mixture of **12** in the S configuration and **13** in the R configuration.

### SCHEME III



5 In Scheme IV, oxidation of racemic **11** with MCPBA gives **13** as a mixture of two enantiomers. See, e.g., Zhou, W.-S. et al., *Tetrahedron* **49**, 2641 (1993). Oxidative rearrangement of tosylate **11** with the S configuration provides **13** as one enantiomer, while starting material of the R configuration gives the other enantiomer.

## SCHEME IV




Amide couplings used to form the compounds of this invention are typically performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester.

Typically, solution phase amide coupling are performed, but solid-phase synthesis by classical Merrified techniques may be employed instead. The addition and removal of one or more protecting groups is also typical practice.

A general synthetic approach to compounds such as A is shown in Scheme V. Grignard addition to 2-furaldehyde 1 provides racemic alcohol 10. Displacement with azide followed by LAH reduction gives racemic amine 9. Coupling

of a peptide or peptidomimetic to amine **9** via the mixed anhydride provides racemic **14**, which is oxidatively rearranged using MCPBA to give compound **15** as a mixture of two enantiomers.

## SCHEME V



5

The compounds of the present invention are useful in the inhibition of viral serine proteases, the prevention or treatment of infection by the human viruses encoding serine proteases, and the treatment of consequent pathological conditions such as Hepatitis C, yellow fever, viral encephalitis, herpes infection. The compounds of the present invention are also useful in the treatment of diseases without apparent viral

etiology, including, but not limited to pulmonary emphysema, cardiovascular disease, cancer, rheumatoid arthritis and immune nephritis.

For these purposes, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous,  
5 intramuscular, intrasternal injection or infusion techniques), by inhalation spray, topically, intravitreally, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.

Thus, in accordance with the present invention there is further provided a method of treating and a pharmaceutical composition for treating infection by human  
10 viruses encoding serine proteases. The treatment involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.

These pharmaceutical compositions may be in the form of orally-  
15 administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions or suppositories.

When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium  
20 alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art. As immediate release tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.

25 When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

30 The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution,

or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.


When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non-irritating  
5 excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.

Dosage levels of the order of 0.02 to 5.0 or 10.0 grams-per-day are useful in the treatment or prevention of the above-indicated conditions, with oral doses  
10 two-to-five times higher. For example, infection by Hepatitis C virus is effectively treated by the administration of from 10 to 50 milligrams of the compound per kilogram of body weight from one to three times per day. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound  
15 employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

The present invention is also directed to combinations of the viral serine  
20 protease inhibitory compounds with one or more agents useful in the treatment of such viruses. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art.

25 It will be understood that the scope of combinations of the compounds of this invention with antivirals, immunomodulators, anti-infectives or vaccines include in principle any combination with any pharmaceutical composition useful for the treatment of diseases resulting from infection by viruses encoding serine protease.


## EXAMPLE 1



5  
2-Isopropyl-2'-furyl carbinol. 2-Furaldehyde (18.25 g, 0.19 mol, 1.00 eq) was dissolved in THF (35 mL) and cooled to 0°C. To this solution, isopropyl  
10 magnesium chloride (99.71 mL, 0.21 mol, 2.0 M in THF, 1.05 eq) was added dropwise. After 2 h, TLC followed the consumption of the starting material, ice-cold NH<sub>4</sub>Cl (5%; 50 mL) was added. The reaction solution was extracted with EtOAc (150 mL), washed with water (3 x 50 mL), dried (MgSO<sub>4</sub>) and concentrated to a light yellow oil. Purification gave 2-isopropyl-2'-furyl carbinol (15.2 g, 0.11 mol, 57%).  
15 Chromatographic purification (Flash column, silica gel, 25 cm x 10 cm, 4/1; hexane/ethyl acetate); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.27 (d, *J*=1.8 Hz, 1 H) 6.24 (dd, *J*<sub>1</sub>=3.0 Hz, *J*<sub>2</sub>=1.8 Hz, 1H) 6.13 (d, *J*=3.0 Hz, 1 H), 4.26 (d, *J*=6.9 Hz, 1H), 2.71 (s, 1 H), 2.00 (sept, *J*=6.6 Hz, 1 H), 0.92 (d, *J*=6.6 Hz, 3 H), 0.77 (d, *J*=6.6 Hz, 3H).

20

## EXAMPLE 2




25 2-Isopropyl-2'-furylmethylazide. Following the procedure of Thompson, A.S., et al., *J. Org. Chem.* **58**, 5886 (1993), 2-isopropyl-2'-furyl carbinol (12.50 g, 89.17 mmol, 1.00 eq) was dissolved in toluene (50 mL) and cooled to 0°C. To this




solution, DBU (16.0 mL, 107.01, 1.20 eq) was added followed by the addition of diphenyl phosphorus azide (12.93 mL, 107.01 mmol, 1.20 eq). The reaction mixture was stirred overnight and concentrated to a solid. The residue was passed through a pad of celite, washed with hexane and concentrated. Purification gave 2-isopropyl-2'-furylmethylazide (9.12 g, 55.21 mmol, 62%). Chromatographic purification (Flash column, silica gel, 25 cm x 10 cm, 19/1; hexane/ethyl acetate). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 Mhz): δ 7.41 (d, *J*=1.2 Hz, 1 H), 6.37 (dd, *J*<sub>1</sub>=3.0 Hz, *J*<sub>2</sub>=1.8 Hz, 1 H), 6.30 (d, *J*=3.0 Hz, 1 H), 4.11 (d, *J*=7.2 Hz, 1 H), 2.19 (sept, *J*=6.6 Hz, 1 H), 1.04 (d, *J*=6.6 Hz, 3 H), 0.88 (d, *J*=6.6 Hz, 3H).

### EXAMPLE 3




2-Isopropyl-2'-furylmethylamine. Following the procedure of Thompson, A.S., et al., *J. Org. Chem.* **58**, 5886 (1993), 2-isopropyl-2'-furylmethylazide (3.00 g, 18.16 mmol, 1.00 eq) was dissolved in THF (40 mL) and cooled to 0°C. To this solution, LAH (36.00 mL, 36.32 mmol, 2.00 eq) was added dropwise. After 2 h, the reaction was warmed to room temperature. The reaction was cooled to -78°C and quenched with water (50 mL). The reaction mixture was extracted with Et<sub>2</sub>O (3 x 100 mL), washed with water (3 x 35 mL), dried (MgSO<sub>4</sub>) and concentrated to give 2-isopropyl-2'-furylmethylamine (2.53 g, 18.16 mmol, 100%) <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.33 (d, *J*=1.8 Hz 1H), 6.30 (dd, *J*<sub>1</sub>=3.0 Hz, *J*<sub>2</sub>=1.8 Hz, 1 H), 6.11 (d, *J*=3.0 Hz, 1 H), 3.69 (d, *J*=6.2 Hz, 1 H), 2.04 (sept, *J*=6.6 Hz, 1 H), 1.04 (d, *J*=6.6 Hz, 3 H), 0.88 (d, *J*=6.6 Hz, 3H).

## EXAMPLE 4



- 5 N-(L-Alanyl-L-alanine acetate)-2-isopropyl-2'-furylmethylamine. L-Alaninyl-L-alanine acetate (1.00 g, 4.95 mmol, 1.00 eq) was dissolved in DMF (15 mL) and THF (30 mL). The reaction mixture was cooled to - 20 °C (acetone/dry ice) and N-methyl morpholine (1.09 mL, 9.91 mmol, 2.00 eq) was added, followed by slow addition of iso-butyl chloroformate (0.70 mL, 5.40 mmol, 1.09 eq). The reaction mixture was stirred at - 20 °C (acetone/dry ice) for 1.5 hr, then cooled to -40 °C (acetone/dry ice), and 2-isopropyl-2'-furylmethylamine (0.83 g, 5.93 mmol, 1.20 eq) was added. The reaction was warmed to room temperature to stand overnight. The solvents were removed under reduced pressure. Purification gave N-(L-alanyl-L-alanine acetate)-2-isopropyl-2'-furylmethylamine as a white solid (1.45 g, 4.48 mmol, 91 %). Data: TLC (silica gel, 1:9; Methanol:EtOAc,  $R_f$  = 0.21); Chromatographic purification ( silica gel, 2.5 cm x 10 cm, 100% hexane to 50% methanol in EtOAc);  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ , 300 MHz):  $\delta$  7.40-7.38 (m, 1 H), 6.33-6.30 (m, 1 H), 6.23-6.16 (m, 1 H), 4.76-4.71 (m, 1 H), 4.41-4.26 (m, 1 H), 2.20-2.13 (m, 1 H), 1.97-1.94 (m, 3), 1.36-1.29 (m, 6H), 0.96-0.82 (m, 6H).  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{OD}$ , 100 MHz):  $\delta$  175.3, 175.1, 174.4, 173.4, 155.6, 142.9, 142.9, 111.2, 107.8, 107.7, 107.6, 54.8, 54.7, 54.6, 50.9, 50.7, 50.5, 50.4, 33.2, 33.1, 22.6, 20.0, 19.4, 19.3, 19.2, 18.5, 18.1, 18.0, 17.7, 17.5. Anal. Calcd for  $\text{C}_{16}\text{H}_{25}\text{N}_3\text{O}_4 \cdot 0.5\text{H}_2\text{O}$ : C, 57.82; H, 7.58; N, 12.64; Found: C, 58.20; H, 7.82; N, 12.61


## EXAMPLE 5



N-(L-Prolyl-L-alanine acetate)-2-isopropyl-2'-furylmethylamine. L-Prolyl-L-alanine  
 5 Acetate (0.78 g, 3.42 mmol, 1.00 eq) was dissolved in DMF (35 mL). The reaction  
 mixture was cooled to - 20 °C (acetone/dry ice), and N-methyl morpholine (0.75 mL,  
 6.84 mmol, 2.00 eq) was added followed by slow addition of iso-butyl chloroformate  
 (0.44 mL, 3.42 mmol, 1.00 eq). The reaction was stirred at - 5 °C (acetone/dry ice) for  
 1.5 hr, then cooled to -40 °C (acetone/dry ice), and 2-isopropyl-2'-furylmethylamine  
 10 (0.50 g, 3.42 mmol, 1.20 eq) was added. The reaction was warmed to room  
 temperature to stand overnight. Work up and purification gave N-(L-prolyl-L-alanine  
 acetate)-2-isopropyl-2'-furylmethylamine (0.82 g, 2.35 mmol, 69%). Data: TLC (silica  
 gel, 1:1; Methanol:EtOAc,  $R_f$  = 0.40); Chromatographic purification ( silica gel, 2.5 cm  
 x 10 cm, 100% hexane to 33 % ethanol in EtOAc);  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ , 300 MHz):  $\delta$   
 15 7.40-7.38 (m, 1 H), 6.33- 6.30 (m, 1 H), 6.23-6.16 (m, 1 H), 4.76-4.71 (m, 1 H), 4.41-  
 4.26 (m, 1 H), 2.20- 2.13 (m, 1 H), 1.97-1.94 (m, 3), 1.36-1.29 (m, 6H), 0.96-0.82 (m,  
 6H).

## EXAMPLE 6

20




N-(L-Prolyl-L-alaninyl-L-alanine acetate)-2-isopropyl-2'-furyl methylamine. L-Prolyl -  
 L-alaninyl-L-alanine acetate (0.72 g, 2.41 mmol, 1.00 eq) was dissolved in DMF (50  
 25 mL). The reaction mixture was cooled to - 20 °C (acetone/dry ice), and N-methyl  
 morpholine (0.58 mL, 5.29 mmol, 2.20 eq) was added followed by slow addition of iso-

butyl chloroformate (0.31 mL, 2.41 mmol, 1.00 eq). The reaction was stirred at -10 °C (acetone/dry ice) for 1.5 hr, then cooled to -40 °C (acetone/dry ice), and 2-isopropyl-2'-furylmethylamine (0.33 g, 2.41 mmol, 1.00 eq) was added. The reaction was warmed to room temperature to stand overnight. The solvents were removed under reduced pressure. Purification gave N-(L-prolyl-L-alaninyl-L-alanine acetate)-2-isopropyl-2'-furylmethylamine (0.83 g, 1.97 mmol, 81 %). Data: TLC (silica gel, EtOAc,  $R_f$  = 0.08); Chromatographic purification (silica gel, 2.5 cm x 10 cm, 50 % hexane in EtOAc to 33% methanol in EtOAc);  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ , 300 MHz):  $\delta$  7.43-7.38 (m, 1 H), 6.34-6.16 (m, 2 H), 4.80-4.32 (m, 3H), 3.82-3.77(m, 1 H), 3.64-3.56 (m, 2H), 2.27-1.99 (m, 8H), 1.35-1.17 (m, 6H), 1.01-0.81(m, 6H).  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{OD}$ , 100 MHz):  $\delta$  174.7, 173.8, 173.8, 173.6, 173.4, 173.3, 173.3, 173.1, 172.9, 172.7, 155.9, 155.7, 155.5, 143.0, 142.9, 142.8, 111.2, 107.8, 107.7, 107.6, 107.5, 63.0, 62.4, 62.1, 61.8, 61.7, 61.6, 61.5, 61.4, 61.0, 60.6, 54.9, 54.8, 54.7, 54.6, 54.4, 50.5, 50.3, 48.4, 48.3, 48.0, 33.5, 33.4, 33.3, 33.1, 32.9, 32.11, 32.9, 30.8, 30.5, 30.2, 30.1, 26.1, 25.9, 25.7, 25.6, 23.6, 23.5, 22.8, 22.6, 22.6, 22.6, 20.1, 20.0, 19.9, 19.6, 19.4, 19.3, 19.0, 18.6, 18.3, 18.2, 17.6, 17.2, 17.1, 17.0, 16.9, 14.6, 15.0.

## EXAMPLE 7


20



N-(L-alanyl-L-alanine acetate)-2-isopropyl-6-hydroxy-1,6-dihydro-3-piperidone. N-(L-alanyl-L-alanine acetate)-2-isopropyl-2'-furylmethylamine (18 mg, 0.06 mmol, 1.00 eq) was dissolved in dichloromethane (10 mL). To this solution, MCPBA (9.4 mg, 0.06 mmol, 1.00 eq) was added via four portions over 10 minutes intervals. After 10 hrs, the solvent was removed and the residue was passed through a pad of silica gel. EtOAc (50 mL) was used to wash away the impurities followed by washing with acetone (25 mL). The acetone solution was concentrated to give N-(L-alanyl-L-alanine acetate)-2-isopropyl-6-hydroxy-1,6-dihydro-3-piperidone as a white solid (15 mg, 0.04 mmol, 79%).  $^1\text{H}$  NMR ( $\text{CD}_3\text{COCD}_3$ , 300 MHz):  $\delta$  7.97-7.01 (m, 4H), 6.09-

6.06 (m, 1 H), 4.35-4.00 (m, 3H), 1.93-1.83 (m, 3H), 1.31-1.14 (m, 3H), 0.95-0.82 (m, 3H). HRMS  $MH^+$  (FAB) Calcd for  $C_{16}H_{26}N_3O_5$ : 340.1872. Found: 340.1871.

5

**EXAMPLE 8**


10

N-(L-Prolyl-L-alanine acetate)-2-isopropyl-6-hydroxy-1,6-dihydro-3-piperidone. N-(L-Prolyl-L-alanine acetate)-2-isopropyl-2'-furylmethylamine (35 mg, 0.10 mmol, 1.00 eq) was dissolved in dichloromethane (10 mL). To this solution, MCPBA (17 mg, 0.10 mmol, 1.00 eq) was added. After 1.2 hr, the solvent was removed and the residue was passed through a pad of silica gel. EtOAc (50 mL) was used to wash away the impurities followed by washing with acetone (25 mL). The acetone solution was concentrated to give a white solid, 25 mg. Chromatographic purification (silica gel, 0.5 cm x 1 cm, EtOAc to 33% acetone) gave N-(L-prolyl-L-alanine acetate)-2-isopropyl-6-hydroxy-1,6-dihydro-3-piperidone (10 mg, 0.03 mmol, 27%)  $^1H$  NMR ( $CDCl_3$ , 300 MHz):  $\delta$  7.33-6.03 (m, 4H), 4.72-4.46 (m, 2H), 4.13-4.01 (m, 2H), 3.82-3.45 (m, 3H), 2.37-1.81 (m, 8H), 1.31-1.26 (m, 3H), 0.99-0.80 (m, 6H).

20

**EXAMPLE 9**

25



N-(L-Prolyl-L-alaninyl-L-alanine acetate)-2-isopropyl-6-hydroxy-1,6-dihydro-3-piperidone. N-(L-Prolyl-L-alaninyl-L-alanine acetate)-2-isopropyl-2-furylmethylamine (46 mg, 0.11 mmol, 1.00 eq) was dissolved in dichloromethane (10 mL). To this solution, MCPBA (24 mg, 0.14 mmol, 1.25 eq) was added. After 1.5 hr, the solvent was removed and the residue was passed through a pad of silica gel. EtOAc (50 mL) was used to wash away the impurities followed by washing with acetone (25 mL). The acetone solution was concentrated to give a white solid, 35 mg. Chromatographic purification (silica gel, 0.5 cm x 1 cm, EtOAc to acetone) gave the title compound (15 mg, 0.03 mmol, 31 %) <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.96- 6.05 (m, 5H), 4.86-4.43 (m, 2H), 4.25-4.05 (m, 2H), 3.85-3.81 (m, 2H), 2.33-1.81 (8H), 1.39-1.27 (m, 6H), 1.00-0.80 (m, 6H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz): δ 173.5, 173.3, 172.9, 172.4, 172.2, 172.1, 171.9, 171.8, 171.6, 171.0, 170.7, 170.1, 155.8, 154.4, 123.0, 122.5, 108.2, 69.8, 61.8, 61.5, 60.6, 60.0, 59.5, 58.5, 58.2, 58.1, 54.0, 49.0, 48.8, 47.4, 47.1, 47.0, 46.7, 46.4, 31.9, 29.9, 29.6, 29.4, 29.3, 29.1, 28.6, 25.4, 25.2, 25.1, 24.8, 24.6, 23.3, 22.7, 21.9, 19.9, 19.3, 19.0, 18.3, 18.1, 17.9, 17.5, 16.5, 14.3. HRMS MLi<sup>+</sup> (FAB) Calcd for C<sub>21</sub>H<sub>32</sub>N<sub>4</sub>O<sub>6</sub>Li: 443.2482. Found: 443.2493.

## EXAMPLE 10

### 20 Porcine Pancreatic Elastase Assay

The assay for inhibition of porcine pancreatic elastase was performed substantially according to Powers, J.C. et al. *Biochemistry* 29 3108. (1990). Porcine pancreatic elastase (PPE), Suc-Ala-Ala-Ala-NA (N-succinyl-alanyl-alanyl-alanine *p*-nitroanilide.), and HEPES were obtained from Sigma Chemical Co., St. Louis, MO. A volume of 50 μL of DMSO and a 50 μL aliquot of PPE solution (5.0 mg PPE dissolved in 5.0 mL 1 mmol HCl) were added to 0.5 mL HEPES buffer (0.1 M HEPES, 0.5 M NaCl, pH 7.5). A 50 μL aliquot of this solution was added to a solution of a 50 μL aliquot of substrate solution (20 mmol Suc-Ala-Ala-Ala-NA in DMSO) in 2.0 mL HEPES buffer. For tubes containing inhibitor, a 50 μL aliquot of inhibitor solution (20 mmole in DMSO) and a 50 μL aliquot of PPE solution were added to 0.5 mL HEPES buffer. Mixture was incubated for 10 minutes before a 50 μL aliquot was added to a

solution of a 50  $\mu$ L aliquot of substrate solution in 2.0 mL Hepes buffer. 4-Nitroanilide hydrolysis was measured at 410 nm ( $\epsilon = 8800 \text{ M}^{-1} \text{ cm}^{-1}$ ) using a spectrophotometer. Slopes obtained for inhibitors were compared those of the corresponding  $V_0$ 's.

- 5                      Compound A was active in the assay, and showed about 20% inhibition at about 17  $\mu$ M.

### EXAMPLE 11


#### Human Cytomegalovirus Protease Assay

- 10                      Inhibition of human cytomegalovirus protease is performed according to Pinko, C. et al., *J.Biol.Chem* 270, 23634 (1995), using either the HPLC-based peptide assay or the continuous RET fluorogenic assay.

- While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood  
15                      that the practice of the invention encompasses all of the usual variations, adaptations, or modifications, as come within the scope of the following claims and its equivalents.

WHAT IS CLAIMED IS:

1. A compound of the formula I



wherein:

10  $\text{---X}$  is a single or a double bond;

X is C or N;

$R^1$  and  $R^4$  are independently selected from the groups consisting of

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl;
- 15 (iii) aryl;
- (iv)  $C_{1-6}\text{-OR}$ , wherein R is H,  $C_{1-6}$  alkyl or aryl;
- (v)  $C_{1-6}\text{-SR}$ ; and
- (vi)  $C_{1-6}\text{-NR}_2$ ;

$R^2$  is

- 20 (i) OH;
- (ii)  $C_{1-6}$  alkyl;
- (iii)  $O\text{-}C_{1-6}$  alkyl;
- (vi) aryl;
- (v)  $C_{1-6}\text{OR}$ ;
- 25 (vi)  $C_{1-6}\text{-SR}$ ; or



(vii)  $C_{1-6}-NR_2$ ;

$R^5$  is

(i) hydrogen;

(ii)  $C_{1-6}$  alkyl;

5 (iii) aryl;

when X is C or when X is N and

-----X is a single bond,

$R^3$  is H or  $(CH_2)_n-Q$ , wherein n is an integer between 1 and 5 and Q is

10 (i) OH;

(ii)  $NH_2$ ;

(iii)  $NHR$ ;

(iv)  $NR_2$ ;

(v)  $COOH$ ;

15 (vi)  $COOR$ ;

(vii)  $SH$ ;

(vii)  $S(O)R$ ; or

(vii)  $SR$ ;

when X is N and

20 -----X is a double bond,

$R^3$  is absent;

when either  $Y_1$  or  $W_1$  are hydrogen or  $Y_1$  and  $W_1$  are both hydrogens, then  $Z_1$  is absent,  $Y_1$  and  $W_1$  are not joined to each other and are independently selected from:

25 (i) hydrogen;

(ii)  $C_{1-6}$  alkyl; or

(iii) aryl;

when  $Y_1$  and  $W_1$  are both not hydrogen, they are selected independently from:

(i)  $-CH_2-$ ;

30 (ii)  $-CHR^1-$ ; or

(iii)  $-CR^1R^4-$ ;

when either  $Y_2$  or  $W_2$  are hydrogen or  $Y_2$  and  $W_2$  are both hydrogens, then  $Z_2$  is absent,  $Y_2$  and  $W_2$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl; or
- (iii) aryl;

when  $Y_2$  and  $W_2$  are both not hydrogen, they are selected independently from:

- (i)  $-CH_2-$ ;
- (ii)  $-CHR^1-$ ; or
- (iii)  $-CR^1R^4-$ ;

$W_3$  is selected from:

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl; or
- (iii) aryl;

$U$  is selected independently from:


- (i) hydrogen;
- (ii)  $-C(O)-C_{1-6}$  alkyl;
- (iii)  $-C(O)-aryl$ ;
- (iv)  $-C(O)-O-C_{1-6}$  alkyl;
- (v)  $-C(O)-O-aryl$ ;
- (vi)  $-C(O)-NH-C_{1-6}$  alkyl; or
- (vii)  $-C(O)-NH-aryl$ ;

$Z_1$  and  $Z_2$  are selected independently from:

- (i)  $-CH_2-$ ;
- (ii)  $-CHR^1-$ ;
- (iii)  $-CR^1R^4-$ ; or
- (iv)  $-CH_2CH_2-$ ;

or pharmaceutically acceptable salts or hydrates thereof.

## 2. A compound of the formula II



5

wherein:

$R^1$  and  $R^4$  are independently selected from the groups consisting of

- (i) hydrogen;
- (ii)  $C_{1-6}$  alkyl;
- (iii) aryl;
- (iv)  $C_{1-6}-OR$ , wherein R is H,  $C_{1-6}$  alkyl or aryl;
- (v)  $C_{1-6}-SR$ ; and
- (vi)  $C_{1-6}-NR_2$ ;

$R^2$  is

- (i) OH;
- (ii)  $C_{1-6}$  alkyl;
- (iii) O- $C_{1-6}$  alkyl;
- (iv) aryl;
- (v)  $C_{1-6}-OR$ ;
- (vi)  $C_{1-6}-SR$ ; or
- (vii)  $C_{1-6}-NR_2$ ;

$R^3$  is H or  $(CH_2)_n-Q$ , wherein n is an integer between 1 and 5 and Q is

- (i) OH;
- (ii)  $NH_2$ ;
- (iii)  $NHR$ ;

25

- (iv)  $\text{NR}_2$ ;
- (v)  $\text{COOH}$ ;
- (vi)  $\text{COOR}$ ;
- (vii)  $\text{SH}$ ;
- (viii)  $\text{S(O)R}$ ; or
- (ix)  $\text{SR}$ ;

$\text{R}^5$  is

- (i) hydrogen;
- (ii)  $\text{C}_{1-6}$  alkyl; or
- (iii) aryl;

when either  $\text{Y}_1$  or  $\text{W}_1$  are hydrogen or  $\text{Y}_1$  and  $\text{W}_1$  are both hydrogens, then  $\text{Z}_1$  is absent,  $\text{Y}_1$  and  $\text{W}_1$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- (ii)  $\text{C}_{1-6}$  alkyl; or
- (iii) aryl;

when  $\text{Y}_1$  and  $\text{W}_1$  are both not hydrogen, they are both  $-\text{CH}_2-$ ;

when either  $\text{Y}_2$  or  $\text{W}_2$  are hydrogen or  $\text{Y}_2$  and  $\text{W}_2$  are both hydrogens, then  $\text{Z}_2$  is absent,  $\text{Y}_2$  and  $\text{W}_2$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- (ii)  $\text{C}_{1-6}$  alkyl; or
- (iii) aryl;

when  $\text{Y}_2$  and  $\text{W}_2$  are both not hydrogen, they are both  $-\text{CH}_2-$ ;

$\text{W}_3$  is:

- (i) hydrogen
- (ii)  $\text{C}_{1-6}$  alkyl; or
- (iii) aryl;

$\text{U}$  is:


- (i) hydrogen;
- (ii)  $-\text{C(O)}-\text{C}_{1-6}$  alkyl;

- (iii) -C(O)-aryl;
- (iv) -C(O)-O-C<sub>1-6</sub> alkyl;
- (v) -C(O)-O-aryl;
- (vi) -C(O)-NH-C<sub>1-6</sub> alkyl;
- (vi) -C(O)-NH-aryl;

Z<sub>1</sub> and Z<sub>2</sub> are both -CH<sub>2</sub>-;

or pharmaceutically acceptable salts or hydrates thereof.

3. A compound of the formula III



wherein:

R<sup>1</sup> is independently selected from the groups consisting of

- (i) hydrogen
- (ii) C<sub>1-6</sub> alkyl;
- (iii) aryl;
- (iv) C<sub>1-6</sub>-OR, wherein R is H, C<sub>1-6</sub> alkyl or aryl;
- (v) C<sub>1-6</sub>-SR; and
- (vi) C<sub>1-6</sub>-NR<sub>2</sub>;

R<sup>2</sup> is

- (i) hydrogen;
- (ii) C<sub>1-6</sub> alkyl; or
- (iii) aryl;

when either  $Y_1$  or  $W_1$  are hydrogen or  $Y_1$  and  $W_1$  are both hydrogens, then  $Z_1$  is absent,  $Y_1$  and  $W_1$  are not joined to each other and are independently selected from:

- (i) hydrogen;
- (ii) C<sub>1-6</sub> alkyl; or
- (iii) aryl;

when  $Y_1$  and  $W_1$  are both not hydrogen, they are both  $-CH_2-$ ;

**$W_2$  is:**

- (i) hydrogen;
- (ii) C<sub>1-6</sub> alkyl; or
- (iii) aryl;

**U is:**


- (i) hydrogen;
- (ii) -C(O)-C<sub>1-6</sub> alkyl;
- (iii) -C(O)-aryl;
- (iv) -C(O)-O-C<sub>1-6</sub> alkyl;
- (v) -C(O)-O-aryl;
- (vi) -C(O)-NH-C<sub>1-6</sub> alkyl; or
- (vii) -C(O)-NH-aryl;

$Z_1$  is  $-\text{CH}_2-$ ;

or pharmaceutically acceptable salts or hydrates thereof.

#### 4. The compound IV

25



or pharmaceutically acceptable salts or hydrates thereof.

5. A pharmaceutical composition comprising a compound of any of claims 1 - 4 and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition of claim 5 useful in the treatment of infections associated with hepatitis C and human cytomegalavirus, encephalitis, pulmonary emphysema, cardiovascular disease, cancer, rheumatoid arthritis and immune nephritis.
7. The pharmaceutical composition of claim 5 useful in the inhibition of the serine proteases of HCV, HCMV, HSV, VZV, EBV and HHV.

## INTERNATIONAL SEARCH REPORT

 International application No.  
 PCT/US98/07709

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07D 403/14, 403/02, 401/14, 401/02; A61K 31/495, 31/435, 31/55

US CL : 544/359, 372, 361, 364; 546/188, 187, 189, 208; 540/597, 602

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 544/359, 372, 361, 364; 546/188, 187, 189, 208; 540/597, 602

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95/07934 A2 (CHIRON CORPORATION) 23 March 1995, entire document.	1-7
A	EP 0 284 942 A2 (MERCK PATENT GESELLSCHAFT) 05 October 1988, entire document.	1-7
A	US 5,340,802 A (SHIOSAKI et al.) 23 August 1994, entire document.	1-7
A	US 5,190,922 A (LULY et al.) 02 March 1993, entire document.	1-7
A	US 4,534,897 A (MOON) 13 August 1985, entire document.	1-7
A	US 4,251,438 A (MOON) 17 February 1981, entire document.	1-7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 JUNE 1998

Date of mailing of the international search report

08 SEP 1998

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MATTHEW V. GRUMBLING

Telephone No. (703) 308-1235